Stage IIIB Cutaneous Melanoma AJCC v7 Recruiting Phase 2 Trials for Trametinib (DB08911)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02910700Nivolumab and Trametinib With or Without Dabrafenib in Treating Patients With BRAF Mutated or Wild Type Metastatic Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT02231775Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationTreatment